Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Angiopoietin-2


Brief Information

Target Synonym:ANGPT2,Angiopoietin 2,ANG-2,Angiopoietin-2B,Angiopoietin-2a,Angiopoietin-2,Tie2-Ligand,AGPT2,ANG2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

Human ANGPT2-coupled Magnetic BeadsHuman ANGPT2-coupled Magnetic Beads (Cat. No. MBS-K035) ELISA bioactivity

Immobilized 47μg ANGPT2 protein/1mg beads can bind Human TIE2 Protein, Fc Tag (Cat. No. TI2-H5255) with an EC50 of 3.228 μg/mL (QC tested).

Human Angiopoietin-2, His TagHuman Angiopoietin-2, His Tag (Cat. No. AN2-H52H4) ELISA bioactivity

Immobilized Human TIE2, Fc Tag (Cat. No. TI2-H5255) at 2 μg/mL (100 μL/well) can bind Human Angiopoietin-2, His Tag (Cat. No. AN2-H52H4) with a linear range of 1-39 ng/mL (QC tested).

Synonym Name



Angiopoietin-2 is also known as ANGPT2, AGPT2, ANG2, and is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Ang2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel Palade bodies. Both Ang2 and the related Angiopoietin1 (Ang1) are ligands for the receptor tyrosine kinase Tie 2. Ang2 functions as a proangiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang2 is required for postnatal vascular remodeling, and it cooperates with Ang1 during lymphatic vessel development. It mediates the upregulation of ICAM1 and VCAM1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang2 competitively inhibit Ang1-induced endothelial cell responses mediated by Tie2, and reduces vascular integrity. But the role of Ang2 is controversial since the opposite outcomes has been reported in other studies. Over-expression of Ang2 disrupts the vascular remodeling, induce endothelial cell apoptosis, and may play an important regulating role in tumor angiogenesis. Ang2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Faricimab RG-7716; RO-6867461 Approved F. Hoffmann-La Roche Ltd, Genentech Inc Vabysmo Japan Macular Degeneration; Diabetic macular oedema Chugai Pharmaceutical Co Ltd 2022-01-28 Macular Edema; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Mellitus; Macular Degeneration; Retinal Vein Occlusion Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RG-6120 RG-6120 Phase 1 Clinical F. Hoffmann-La Roche Ltd Macular Degeneration Details
IBI-324 IBI-324 Phase 1 Clinical Innovent Biologics (Usa), Inc Diabetic macular oedema Details
RO-7250284 RO-7250284 F. Hoffmann-La Roche Ltd Details
Nesvacumab REGN-910; SAR-307746 Regeneron Pharmaceuticals Inc, Sanofi Details
Trebananib AMG-386; 20060439 Amgen Inc, Takeda Pharmaceutical Co Ltd Details
PF-4856884 CVX-060; CovX 060; PF-04856884 Covx Pharmaceuticals, Pfizer Inc Details
MEDI-3617 ANG-2-mAb; MEDI-3617; Anti-ANG-2-mAb Medimmune Details
Aflibercept/Nesvacumab REGN 910-3 Regeneron Pharmaceuticals Inc Details
PF-5057459 CVX-241; CovX-241; PF-05057459 Pfizer Pharmaceuticals Ltd (China) Details
Zansecimab LY-3127804 Eli Lilly And Company Details
Vanucizumab RG-7221; RO-5520985; B800Z06O8K (UNII code) F. Hoffmann-La Roche Ltd Details
BI-836880 BI-836880 Phase 1 Clinical Ablynx Squamous Cell Carcinoma of Head and Neck; Neoplasms; Wet Macular Degeneration; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
ASKG-712 AM-712; ASKG-712 Phase 1 Clinical Askgene Pharma Wet Macular Degeneration; Macular Degeneration Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message